Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyBarbital
Identification
- Name
- Barbital
- Accession Number
- DB01483
- Type
- Small Molecule
- Groups
- Illicit
- Description
A long-acting barbiturate that depresses most metabolic processes at high doses. It is used as a hypnotic and sedative and may induce dependence. Barbital is also used in veterinary practice for central nervous system depression. Barbital is a schedule IV controlled drug.
- Structure
Structure for DB01483 (Barbital)
- Synonyms
- Not Available
- Categories
- UNII
- 5WZ53ENE2P
- CAS number
- 57-44-3
- Weight
- Average: 184.1925
Monoisotopic: 184.08479226 - Chemical Formula
- C8H12N2O3
- InChI Key
- FTOAOBMCPZCFFF-UHFFFAOYSA-N
- InChI
- InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13)
- IUPAC Name
- 5,5-diethyl-1,3-diazinane-2,4,6-trione
- SMILES
- CCC1(CC)C(=O)NC(=O)NC1=O
Pharmacology
- Indication
- Not Available
- Structured Indications
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism AGamma-aminobutyric acid receptor subunit alpha-1 potentiatorHuman AGamma-aminobutyric acid receptor subunit alpha-2 potentiatorHuman AGamma-aminobutyric acid receptor subunit alpha-3 potentiatorHuman AGamma-aminobutyric acid receptor subunit alpha-4 potentiatorHuman AGamma-aminobutyric acid receptor subunit alpha-5 potentiatorHuman AGamma-aminobutyric acid receptor subunit alpha-6 potentiatorHuman UNeuronal acetylcholine receptor subunit alpha-4 antagonistHuman UNeuronal acetylcholine receptor subunit alpha-7 antagonistHuman UGlutamate receptor 2 antagonistHuman UGlutamate receptor ionotropic, kainate 2 antagonistHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when Barbital is combined with 7-Nitroindazole. Experimental Acebutolol The serum concentration of Acebutolol can be decreased when it is combined with Barbital. Approved, Investigational Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Barbital. Approved, Investigational Acepromazine The risk or severity of adverse effects can be increased when Barbital is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Barbital is combined with Aceprometazine. Approved Acetaminophen The metabolism of Acetaminophen can be increased when combined with Barbital. Approved Adipiplon The risk or severity of adverse effects can be increased when Barbital is combined with Adipiplon. Investigational Agmatine The metabolism of Agmatine can be increased when combined with Barbital. Experimental, Investigational Agomelatine The risk or severity of adverse effects can be increased when Barbital is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Barbital is combined with Alaproclate. Experimental Aldesleukin Barbital may increase the hypotensive activities of Aldesleukin. Approved Alfaxalone The risk or severity of adverse effects can be increased when Barbital is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Barbital. Approved, Illicit Aliskiren Barbital may increase the hypotensive activities of Aliskiren. Approved, Investigational Allopregnanolone The risk or severity of adverse effects can be increased when Barbital is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Barbital is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Barbital is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Barbital. Approved, Illicit, Investigational Alprenolol The serum concentration of Alprenolol can be decreased when it is combined with Barbital. Approved, Withdrawn Ambroxol acefyllinate The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Barbital. Experimental, Investigational Amifostine Barbital may increase the hypotensive activities of Amifostine. Approved, Investigational Amiloride Barbital may increase the hypotensive activities of Amiloride. Approved Amineptine The metabolism of Amineptine can be increased when combined with Barbital. Illicit, Withdrawn Aminophylline The serum concentration of Aminophylline can be decreased when it is combined with Barbital. Approved Amiodarone Barbital may increase the hypotensive activities of Amiodarone. Approved, Investigational Amisulpride The risk or severity of adverse effects can be increased when Barbital is combined with Amisulpride. Approved, Investigational Amitriptyline The metabolism of Amitriptyline can be increased when combined with Barbital. Approved Amlodipine The metabolism of Amlodipine can be increased when combined with Barbital. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Barbital. Approved, Illicit Amoxapine The metabolism of Amoxapine can be increased when combined with Barbital. Approved Amperozide The risk or severity of adverse effects can be increased when Barbital is combined with Amperozide. Experimental Amphotericin B Barbital may increase the hypotensive activities of Amphotericin B. Approved, Investigational Amrinone The metabolism of Amrinone can be increased when combined with Barbital. Approved Amyl Nitrite Barbital may increase the hypotensive activities of Amyl Nitrite. Approved Apomorphine Barbital may increase the hypotensive activities of Apomorphine. Approved, Investigational Apraclonidine Barbital may increase the hypotensive activities of Apraclonidine. Approved Aranidipine The metabolism of Aranidipine can be increased when combined with Barbital. Approved, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Barbital. Approved, Investigational Arotinolol The serum concentration of Arotinolol can be decreased when it is combined with Barbital. Investigational Arsenic trioxide Barbital may increase the hypotensive activities of Arsenic trioxide. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Barbital is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Barbital. Approved Atenolol The serum concentration of Atenolol can be decreased when it is combined with Barbital. Approved Azaperone The risk or severity of adverse effects can be increased when Barbital is combined with Azaperone. Investigational, Vet Approved Azelastine Barbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Azelnidipine The metabolism of Azelnidipine can be increased when combined with Barbital. Approved, Investigational Azilsartan medoxomil Barbital may increase the hypotensive activities of Azilsartan medoxomil. Approved, Investigational Azimilide The metabolism of Azimilide can be increased when combined with Barbital. Investigational Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Barbital. Approved Barnidipine The metabolism of Barnidipine can be increased when combined with Barbital. Approved Befunolol The serum concentration of Befunolol can be decreased when it is combined with Barbital. Experimental Benazepril Barbital may increase the hypotensive activities of Benazepril. Approved, Investigational Bencyclane The metabolism of Bencyclane can be increased when combined with Barbital. Experimental Bendroflumethiazide Barbital may increase the orthostatic hypotensive activities of Bendroflumethiazide. Approved Benidipine The metabolism of Benidipine can be increased when combined with Barbital. Approved, Investigational Benperidol The risk or severity of adverse effects can be increased when Barbital is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Benzocaine is combined with Barbital. Approved, Investigational Benzyl alcohol The risk or severity of adverse effects can be increased when Barbital is combined with Benzyl alcohol. Approved Bepridil The metabolism of Bepridil can be increased when combined with Barbital. Approved, Withdrawn Betaxolol The serum concentration of Betaxolol can be decreased when it is combined with Barbital. Approved, Investigational Bevantolol The serum concentration of Bevantolol can be decreased when it is combined with Barbital. Approved Bioallethrin The metabolism of Bioallethrin can be increased when combined with Barbital. Approved, Experimental Bisoprolol The serum concentration of Bisoprolol can be decreased when it is combined with Barbital. Approved Bopindolol The serum concentration of Bopindolol can be decreased when it is combined with Barbital. Approved Bortezomib Barbital may increase the hypotensive activities of Bortezomib. Approved, Investigational Bretylium Barbital may increase the hypotensive activities of Bretylium. Approved Brexpiprazole The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Barbital. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Barbital. Approved Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Barbital. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Barbital is combined with Bromisoval. Experimental Bromocriptine Barbital may increase the hypotensive activities of Bromocriptine. Approved, Investigational Bromperidol The risk or severity of adverse effects can be increased when Barbital is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Barbital. Approved Brotizolam The risk or severity of adverse effects can be increased when Barbital is combined with Brotizolam. Approved, Investigational, Withdrawn Bucindolol The serum concentration of Bucindolol can be decreased when it is combined with Barbital. Investigational Bufuralol The serum concentration of Bufuralol can be decreased when it is combined with Barbital. Experimental, Investigational Bumetanide Barbital may increase the hypotensive activities of Bumetanide. Approved Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Barbital. Approved, Investigational Bupranolol The serum concentration of Bupranolol can be decreased when it is combined with Barbital. Approved Buprenorphine Barbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Barbital. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Barbital. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Barbital is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Barbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Barbital is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Butethal is combined with Barbital. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Barbital. Approved, Illicit, Vet Approved Canagliflozin Barbital may increase the hypotensive activities of Canagliflozin. Approved Candesartan cilexetil Barbital may increase the hypotensive activities of Candesartan cilexetil. Approved Canertinib The risk or severity of adverse effects can be increased when Barbital is combined with Canertinib. Investigational Captopril Barbital may increase the hypotensive activities of Captopril. Approved Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Barbital. Approved, Investigational Carbetocin Barbital may increase the hypotensive activities of Carbetocin. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Barbital. Approved Carboxyamidotriazole The metabolism of Carboxyamidotriazole can be increased when combined with Barbital. Investigational Carfentanil The risk or severity of adverse effects can be increased when Barbital is combined with Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Barbital. Approved Caroverine The metabolism of Caroverine can be increased when combined with Barbital. Experimental Carteolol The serum concentration of Carteolol can be decreased when it is combined with Barbital. Approved Carvedilol The serum concentration of Carvedilol can be decreased when it is combined with Barbital. Approved, Investigational Celiprolol The serum concentration of Celiprolol can be decreased when it is combined with Barbital. Approved, Investigational Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Barbital. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Barbital is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chloramphenicol The metabolism of Barbital can be decreased when combined with Chloramphenicol. Approved, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Barbital. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Chlormezanone is combined with Barbital. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Barbital. Approved Chlorothiazide Barbital may increase the orthostatic hypotensive activities of Chlorothiazide. Approved, Vet Approved Chlorotrianisene The therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Barbital. Investigational, Withdrawn Chlorphenamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Barbital. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Barbital. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Barbital. Approved, Investigational, Withdrawn Chlorthalidone Barbital may increase the orthostatic hypotensive activities of Chlorthalidone. Approved Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Barbital. Approved Cilazapril Barbital may increase the hypotensive activities of Cilazapril. Approved Cilnidipine The metabolism of Cilnidipine can be increased when combined with Barbital. Approved, Investigational Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Barbital. Approved, Vet Approved Cinnarizine The metabolism of Cinnarizine can be increased when combined with Barbital. Approved, Investigational Citalopram The risk or severity of adverse effects can be increased when Barbital is combined with Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Clemastine is combined with Barbital. Approved, Investigational Clevidipine The metabolism of Clevidipine can be increased when combined with Barbital. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Barbital. Approved Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Barbital. Approved, Illicit Clofarabine Barbital may increase the hypotensive activities of Clofarabine. Approved, Investigational clomethiazole The risk or severity of adverse effects can be increased when Barbital is combined with clomethiazole. Investigational Clomipramine The metabolism of Clomipramine can be increased when combined with Barbital. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Barbital. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Clonidine is combined with Barbital. Approved Clopenthixol The risk or severity of adverse effects can be increased when Barbital is combined with Clopenthixol. Experimental Cloranolol The serum concentration of Cloranolol can be decreased when it is combined with Barbital. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Barbital. Approved, Illicit Clorindione The metabolism of Clorindione can be increased when combined with Barbital. Experimental Clothiapine The risk or severity of adverse effects can be increased when Barbital is combined with Clothiapine. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Barbital. Approved Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Barbital. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Barbital. Approved, Illicit Conivaptan Barbital may increase the hypotensive activities of Conivaptan. Approved, Investigational Conjugated estrogens The therapeutic efficacy of Conjugated estrogens can be decreased when used in combination with Barbital. Approved Cyclandelate The metabolism of Cyclandelate can be increased when combined with Barbital. Approved Cyclizine The risk or severity of adverse effects can be increased when Cyclizine is combined with Barbital. Approved Cyclobenzaprine The metabolism of Cyclobenzaprine can be increased when combined with Barbital. Approved Cyclopenthiazide Barbital may increase the orthostatic hypotensive activities of Cyclopenthiazide. Experimental Cyclopropane The risk or severity of adverse effects can be increased when Barbital is combined with Cyclopropane. Experimental Cyclosporine The metabolism of Cyclosporine can be increased when combined with Barbital. Approved, Investigational, Vet Approved Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Barbital. Approved Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Barbital. Approved, Investigational Dapagliflozin Barbital may increase the hypotensive activities of Dapagliflozin. Approved Dapiprazole The risk or severity of adverse effects can be increased when Dapiprazole is combined with Barbital. Approved Dapoxetine The risk or severity of adverse effects can be increased when Barbital is combined with Dapoxetine. Investigational Darodipine The metabolism of Darodipine can be increased when combined with Barbital. Experimental Deramciclane The risk or severity of adverse effects can be increased when Barbital is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Barbital. Approved Desipramine The metabolism of Desipramine can be increased when combined with Barbital. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Barbital. Approved, Investigational Desogestrel The therapeutic efficacy of Desogestrel can be decreased when used in combination with Barbital. Approved Desvenlafaxine The risk or severity of adverse effects can be increased when Barbital is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Barbital is combined with Detomidine. Vet Approved Deutetrabenazine The risk or severity of sedation and somnolence can be increased when Barbital is combined with Deutetrabenazine. Approved, Investigational Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Barbital. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Barbital. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Barbital is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Barbital. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Barbital. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Barbital. Approved, Illicit, Investigational, Vet Approved Dibenzepin The metabolism of Dibenzepin can be increased when combined with Barbital. Experimental Diclofenamide Barbital may increase the hypotensive activities of Diclofenamide. Approved, Investigational Dicoumarol The metabolism of Dicoumarol can be increased when combined with Barbital. Approved Dienestrol The therapeutic efficacy of Dienestrol can be decreased when used in combination with Barbital. Approved, Investigational Dienogest The therapeutic efficacy of Dienogest can be decreased when used in combination with Barbital. Approved Diethyl ether The risk or severity of adverse effects can be increased when Barbital is combined with Diethyl ether. Experimental Diethylstilbestrol The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Barbital. Approved, Investigational Difenoxin The risk or severity of adverse effects can be increased when Difenoxin is combined with Barbital. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Barbital. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Barbital. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Barbital is combined with Dihydromorphine. Experimental, Illicit Diltiazem The metabolism of Diltiazem can be increased when combined with Barbital. Approved, Investigational Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Barbital. Approved Dinutuximab Barbital may increase the hypotensive activities of Dinutuximab. Approved, Investigational Diphenadione The metabolism of Diphenadione can be increased when combined with Barbital. Experimental Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Barbital. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Barbital. Approved, Illicit Dipyridamole Barbital may increase the hypotensive activities of Dipyridamole. Approved Dixyrazine The risk or severity of adverse effects can be increased when Barbital is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Barbital is combined with Doramectin. Vet Approved Dosulepin The metabolism of Dosulepin can be increased when combined with Barbital. Approved Dotarizine The metabolism of Dotarizine can be increased when combined with Barbital. Investigational Doxazosin Barbital may increase the hypotensive activities of Doxazosin. Approved Doxepin The metabolism of Doxepin can be increased when combined with Barbital. Approved, Investigational Doxycycline The serum concentration of Doxycycline can be decreased when it is combined with Barbital. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Barbital. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Barbital is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Barbital. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Barbital. Approved, Vet Approved Drospirenone The therapeutic efficacy of Drospirenone can be decreased when used in combination with Barbital. Approved Drotebanol The risk or severity of adverse effects can be increased when Barbital is combined with Drotebanol. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Barbital is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Dyclonine is combined with Barbital. Approved Dyphylline The serum concentration of Dyphylline can be decreased when it is combined with Barbital. Approved Ecgonine The risk or severity of adverse effects can be increased when Barbital is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Barbital is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Barbital. Approved, Investigational Efonidipine The metabolism of Efonidipine can be increased when combined with Barbital. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Barbital is combined with Eltanolone. Investigational Empagliflozin Barbital may increase the hypotensive activities of Empagliflozin. Approved Enalapril Barbital may increase the hypotensive activities of Enalapril. Approved, Vet Approved Enalaprilat Barbital may increase the hypotensive activities of Enalaprilat. Approved Enflurane The risk or severity of adverse effects can be increased when Enflurane is combined with Barbital. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Barbital. Approved, Investigational Epanolol The serum concentration of Epanolol can be decreased when it is combined with Barbital. Experimental Eperisone The metabolism of Eperisone can be increased when combined with Barbital. Approved, Investigational Epitizide Barbital may increase the orthostatic hypotensive activities of Epitizide. Experimental Eplerenone Barbital may increase the hypotensive activities of Eplerenone. Approved Epoprostenol Barbital may increase the hypotensive activities of Epoprostenol. Approved Eprosartan Barbital may increase the hypotensive activities of Eprosartan. Approved Escitalopram The risk or severity of adverse effects can be increased when Barbital is combined with Escitalopram. Approved, Investigational Esmirtazapine The metabolism of Esmirtazapine can be increased when combined with Barbital. Investigational Esmolol The serum concentration of Esmolol can be decreased when it is combined with Barbital. Approved Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Barbital. Approved, Illicit Estradiol The therapeutic efficacy of Estradiol can be decreased when used in combination with Barbital. Approved, Investigational, Vet Approved Estramustine The therapeutic efficacy of Estramustine can be decreased when used in combination with Barbital. Approved, Investigational Estrogens, esterified The therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Barbital. Approved Estrone sulfate The therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Barbital. Approved Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Barbital. Approved, Investigational Etacrynic acid Barbital may increase the hypotensive activities of Etacrynic acid. Approved, Investigational Ethanol Barbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Barbital. Approved, Illicit, Withdrawn Ethinyl Estradiol The therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Barbital. Approved Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Barbital. Approved Ethotoin The risk or severity of adverse effects can be increased when Ethotoin is combined with Barbital. Approved Ethyl biscoumacetate The metabolism of Ethyl biscoumacetate can be increased when combined with Barbital. Withdrawn Ethyl carbamate The risk or severity of adverse effects can be increased when Barbital is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Barbital is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Barbital is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Barbital. Approved, Illicit Ethynodiol diacetate The therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Barbital. Approved Etidocaine The risk or severity of adverse effects can be increased when Barbital is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Barbital is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Barbital is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Barbital. Approved Etonogestrel The therapeutic efficacy of Etonogestrel can be decreased when used in combination with Barbital. Approved, Investigational Etoperidone The risk or severity of adverse effects can be increased when Barbital is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Barbital is combined with Etorphine. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Ezogabine is combined with Barbital. Approved, Investigational Felbamate The serum concentration of Barbital can be increased when it is combined with Felbamate. Approved Felodipine The metabolism of Felodipine can be increased when combined with Barbital. Approved, Investigational Fencamfamine The risk or severity of adverse effects can be increased when Fencamfamine is combined with Barbital. Approved, Illicit, Withdrawn Fendiline The metabolism of Fendiline can be increased when combined with Barbital. Withdrawn Fenoldopam Barbital may increase the hypotensive activities of Fenoldopam. Approved Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Barbital. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Fexofenadine is combined with Barbital. Approved, Investigational Fimasartan Barbital may increase the hypotensive activities of Fimasartan. Approved, Investigational Fish oil The metabolism of Fish oil can be increased when combined with Barbital. Approved, Nutraceutical Flibanserin The risk or severity of adverse effects can be increased when Flibanserin is combined with Barbital. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Barbital is combined with Fluanisone. Experimental Fludiazepam The risk or severity of adverse effects can be increased when Barbital is combined with Fludiazepam. Approved, Illicit Fluindione The metabolism of Fluindione can be increased when combined with Barbital. Approved, Investigational Flunarizine The metabolism of Flunarizine can be increased when combined with Barbital. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Barbital is combined with Flunitrazepam. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Barbital is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Barbital. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Barbital. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Barbital. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Barbital is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Barbital. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Barbital. Approved, Investigational Fosinopril Barbital may increase the hypotensive activities of Fosinopril. Approved Fosphenytoin The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Barbital. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Barbital is combined with Fospropofol. Approved, Illicit, Investigational Furosemide Barbital may increase the hypotensive activities of Furosemide. Approved, Vet Approved Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Barbital. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Barbital. Approved, Investigational Gallopamil The metabolism of Gallopamil can be increased when combined with Barbital. Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Barbital. Approved, Illicit, Investigational Gepirone The risk or severity of adverse effects can be increased when Barbital is combined with Gepirone. Investigational Gestodene The therapeutic efficacy of Gestodene can be decreased when used in combination with Barbital. Approved, Investigational Glutethimide The risk or severity of adverse effects can be increased when Glutethimide is combined with Barbital. Approved, Illicit Griseofulvin The serum concentration of Griseofulvin can be decreased when it is combined with Barbital. Approved, Investigational, Vet Approved Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Barbital. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Halazepam is combined with Barbital. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Barbital. Approved Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Barbital. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Barbital. Approved, Illicit, Investigational Hexestrol The therapeutic efficacy of Hexestrol can be decreased when used in combination with Barbital. Withdrawn Hexobarbital The risk or severity of adverse effects can be increased when Hexobarbital is combined with Barbital. Approved Hydralazine Barbital may increase the hypotensive activities of Hydralazine. Approved Hydrochlorothiazide Barbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide. Approved, Vet Approved Hydrocodone Barbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydroflumethiazide Barbital may increase the orthostatic hypotensive activities of Hydroflumethiazide. Approved, Investigational Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Barbital. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Barbital. Approved Iloperidone The risk or severity of adverse effects can be increased when Iloperidone is combined with Barbital. Approved Iloprost Barbital may increase the hypotensive activities of Iloprost. Approved, Investigational Imidapril Barbital may increase the hypotensive activities of Imidapril. Investigational Imipramine The metabolism of Imipramine can be increased when combined with Barbital. Approved Indalpine The risk or severity of adverse effects can be increased when Barbital is combined with Indalpine. Investigational, Withdrawn Indapamide Barbital may increase the orthostatic hypotensive activities of Indapamide. Approved Indenolol The serum concentration of Indenolol can be decreased when it is combined with Barbital. Withdrawn Indiplon The risk or severity of adverse effects can be increased when Barbital is combined with Indiplon. Investigational Indoramin Barbital may increase the hypotensive activities of Indoramin. Withdrawn Iprindole The metabolism of Iprindole can be increased when combined with Barbital. Experimental Irbesartan Barbital may increase the hypotensive activities of Irbesartan. Approved, Investigational Isocarboxazid Barbital may increase the hypotensive activities of Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Barbital. Approved, Vet Approved Isosorbide Dinitrate Barbital may increase the hypotensive activities of Isosorbide Dinitrate. Approved, Investigational Isosorbide Mononitrate Barbital may increase the hypotensive activities of Isosorbide Mononitrate. Approved Isoxsuprine Barbital may increase the hypotensive activities of Isoxsuprine. Approved, Withdrawn Isradipine The metabolism of Isradipine can be increased when combined with Barbital. Approved, Investigational Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Barbital. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Barbital is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Barbital is combined with Ketobemidone. Approved, Investigational Labetalol The serum concentration of Labetalol can be decreased when it is combined with Barbital. Approved Lacidipine The metabolism of Lacidipine can be increased when combined with Barbital. Approved, Investigational Lamotrigine The serum concentration of Lamotrigine can be decreased when it is combined with Barbital. Approved, Investigational Landiolol The serum concentration of Landiolol can be decreased when it is combined with Barbital. Investigational Lercanidipine The metabolism of Lercanidipine can be increased when combined with Barbital. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Barbital. Approved, Investigational Levobunolol The serum concentration of Levobunolol can be decreased when it is combined with Barbital. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Barbital. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Barbital is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Levocetirizine is combined with Barbital. Approved Levodopa Barbital may increase the hypotensive activities of Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Barbital. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Barbital is combined with Levomilnacipran. Approved, Investigational Levonorgestrel The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Barbital. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Barbital. Approved Levosimendan Barbital may increase the hypotensive activities of Levosimendan. Approved, Investigational Lidocaine The risk or severity of adverse effects can be increased when Lidocaine is combined with Barbital. Approved, Vet Approved Lidoflazine The metabolism of Lidoflazine can be increased when combined with Barbital. Experimental Lisinopril Barbital may increase the hypotensive activities of Lisinopril. Approved, Investigational Lithium The risk or severity of adverse effects can be increased when Lithium is combined with Barbital. Approved Lofentanil The risk or severity of adverse effects can be increased when Barbital is combined with Lofentanil. Illicit Lofepramine The metabolism of Lofepramine can be increased when combined with Barbital. Experimental Lofexidine Barbital may increase the hypotensive activities of Lofexidine. Approved, Investigational Loperamide The metabolism of Loperamide can be increased when combined with Barbital. Approved Loprazolam The risk or severity of adverse effects can be increased when Barbital is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with Barbital. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Barbital. Approved Lormetazepam The risk or severity of adverse effects can be increased when Barbital is combined with Lormetazepam. Approved Losartan Barbital may increase the hypotensive activities of Losartan. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Barbital. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Barbital. Approved, Investigational Lynestrenol The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Barbital. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Barbital can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Manidipine The metabolism of Manidipine can be increased when combined with Barbital. Approved, Investigational Mannitol Barbital may increase the hypotensive activities of Mannitol. Approved, Investigational Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Barbital. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Barbital is combined with Mebicar. Experimental Mecamylamine Barbital may increase the hypotensive activities of Mecamylamine. Approved, Investigational Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Barbital. Approved Medazepam The risk or severity of adverse effects can be increased when Barbital is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Barbital is combined with Medetomidine. Vet Approved Medrogestone The serum concentration of Medrogestone can be decreased when it is combined with Barbital. Approved Medroxyprogesterone acetate The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Barbital. Approved, Investigational Melatonin The risk or severity of adverse effects can be increased when Melatonin is combined with Barbital. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Barbital is combined with Melperone. Approved, Investigational Mepindolol The serum concentration of Mepindolol can be decreased when it is combined with Barbital. Experimental Mepivacaine The risk or severity of adverse effects can be increased when Mepivacaine is combined with Barbital. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Barbital. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Barbital is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Mesoridazine is combined with Barbital. Approved, Investigational Mestranol The therapeutic efficacy of Mestranol can be decreased when used in combination with Barbital. Approved Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Barbital. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Barbital. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Barbital. Approved, Illicit Methallenestril The therapeutic efficacy of Methallenestril can be decreased when used in combination with Barbital. Experimental Methapyrilene The risk or severity of adverse effects can be increased when Barbital is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Barbital is combined with Methaqualone. Illicit, Withdrawn Methazolamide Barbital may increase the hypotensive activities of Methazolamide. Approved Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Barbital. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Barbital. Approved Methotrimeprazine Barbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Barbital. Approved, Investigational, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Barbital. Approved Methyclothiazide Barbital may increase the orthostatic hypotensive activities of Methyclothiazide. Approved Methyldopa Barbital may increase the hypotensive activities of Methyldopa. Approved Methylecgonine The risk or severity of adverse effects can be increased when Barbital is combined with Methylecgonine. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Barbital. Approved Metipranolol The serum concentration of Metipranolol can be decreased when it is combined with Barbital. Approved Metolazone Barbital may increase the orthostatic hypotensive activities of Metolazone. Approved Metoprolol The serum concentration of Metoprolol can be decreased when it is combined with Barbital. Approved, Investigational Metyrosine Barbital may increase the sedative activities of Metyrosine. Approved Mianserin Mianserin may increase the central nervous system depressant (CNS depressant) activities of Barbital. Approved, Investigational Mibefradil The metabolism of Mibefradil can be increased when combined with Barbital. Investigational, Withdrawn Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Barbital. Approved, Illicit Milnacipran The risk or severity of adverse effects can be increased when Barbital is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Barbital. Approved, Investigational Minoxidil Barbital may increase the hypotensive activities of Minoxidil. Approved, Investigational Mirtazapine Barbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Moexipril Barbital may increase the hypotensive activities of Moexipril. Approved Molindone The risk or severity of adverse effects can be increased when Barbital is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Barbital. Approved, Investigational Moxonidine Barbital may increase the hypotensive activities of Moxonidine. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Barbital. Approved, Investigational Nadolol The serum concentration of Nadolol can be decreased when it is combined with Barbital. Approved Naftopidil The metabolism of Naftopidil can be increased when combined with Barbital. Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Barbital. Approved Nebivolol The serum concentration of Nebivolol can be decreased when it is combined with Barbital. Approved, Investigational Nefazodone The risk or severity of adverse effects can be increased when Barbital is combined with Nefazodone. Approved, Withdrawn Nesiritide Barbital may increase the hypotensive activities of Nesiritide. Approved, Investigational Nicardipine The metabolism of Nicardipine can be increased when combined with Barbital. Approved, Investigational Nifedipine The metabolism of Nifedipine can be increased when combined with Barbital. Approved Niguldipine The metabolism of Niguldipine can be increased when combined with Barbital. Experimental Niludipine The metabolism of Niludipine can be increased when combined with Barbital. Experimental Nilvadipine The metabolism of Nilvadipine can be increased when combined with Barbital. Approved, Investigational Nimesulide The metabolism of Nimesulide can be increased when combined with Barbital. Approved, Investigational, Withdrawn Nimodipine The metabolism of Nimodipine can be increased when combined with Barbital. Approved, Investigational Nisoldipine The metabolism of Nisoldipine can be increased when combined with Barbital. Approved Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Barbital. Approved Nitrendipine The metabolism of Nitrendipine can be increased when combined with Barbital. Approved, Investigational Nitric Oxide Barbital may increase the hypotensive activities of Nitric Oxide. Approved Nitroglycerin Barbital may increase the hypotensive activities of Nitroglycerin. Approved, Investigational Nitroprusside Barbital may increase the hypotensive activities of Nitroprusside. Approved, Investigational Nitrous acid Barbital may increase the hypotensive activities of Nitrous acid. Approved, Investigational Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Barbital. Approved, Vet Approved Norelgestromin The therapeutic efficacy of Norelgestromin can be decreased when used in combination with Barbital. Approved, Investigational Norflurane The risk or severity of adverse effects can be increased when Barbital is combined with Norflurane. Approved, Investigational Norgestimate The therapeutic efficacy of Norgestimate can be decreased when used in combination with Barbital. Approved, Investigational Norgestrel The therapeutic efficacy of Norgestrel can be decreased when used in combination with Barbital. Approved Normethadone The risk or severity of adverse effects can be increased when Barbital is combined with Normethadone. Approved, Illicit Nortriptyline The metabolism of Nortriptyline can be increased when combined with Barbital. Approved Nylidrin The metabolism of Nylidrin can be increased when combined with Barbital. Approved Obinutuzumab Barbital may increase the hypotensive activities of Obinutuzumab. Approved, Investigational Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Barbital. Approved, Investigational Olmesartan Barbital may increase the hypotensive activities of Olmesartan. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Barbital. Approved Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Barbital. Approved Opipramol The metabolism of Opipramol can be increased when combined with Barbital. Investigational Opium The risk or severity of adverse effects can be increased when Barbital is combined with Opium. Approved, Illicit Orphenadrine Barbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Barbital is combined with Osanetant. Investigational Otilonium The metabolism of Otilonium can be increased when combined with Barbital. Experimental, Investigational Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Barbital. Approved Oxethazaine The risk or severity of adverse effects can be increased when Barbital is combined with Oxethazaine. Approved, Investigational Oxprenolol The risk or severity of adverse effects can be increased when Barbital is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Barbital. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Barbital. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Barbital. Approved, Investigational, Vet Approved Paclitaxel Barbital may increase the hypotensive activities of Paclitaxel. Approved, Vet Approved Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Barbital. Approved Papaverine Barbital may increase the hypotensive activities of Papaverine. Approved, Investigational Paraldehyde Barbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Barbital is combined with Paroxetine. Approved, Investigational Penbutolol The serum concentration of Penbutolol can be decreased when it is combined with Barbital. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Barbital is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Barbital. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Barbital. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Barbital. Approved Perazine The risk or severity of adverse effects can be increased when Barbital is combined with Perazine. Approved, Investigational Perindopril Barbital may increase the hypotensive activities of Perindopril. Approved Perospirone The risk or severity of adverse effects can be increased when Barbital is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Barbital. Approved Pethidine Barbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine. Approved Phenazocine The risk or severity of adverse effects can be increased when Barbital is combined with Phenazocine. Experimental Phenelzine Barbital may increase the hypotensive activities of Phenelzine. Approved Phenibut The risk or severity of adverse effects can be increased when Barbital is combined with Phenibut. Experimental Phenindione The metabolism of Phenindione can be increased when combined with Barbital. Approved, Investigational Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Barbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Barbital is combined with Phenoperidine. Experimental Phenoxybenzamine Barbital may increase the hypotensive activities of Phenoxybenzamine. Approved Phenoxyethanol The risk or severity of adverse effects can be increased when Barbital is combined with Phenoxyethanol. Approved Phenprocoumon The metabolism of Phenprocoumon can be increased when combined with Barbital. Approved, Investigational Phentolamine Barbital may increase the hypotensive activities of Phentolamine. Approved Phenytoin The risk or severity of adverse effects can be increased when Phenytoin is combined with Barbital. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Barbital. Approved Pinaverium The metabolism of Pinaverium can be increased when combined with Barbital. Approved Pindolol The serum concentration of Pindolol can be decreased when it is combined with Barbital. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Barbital is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Pipotiazine is combined with Barbital. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Barbital is combined with Piritramide. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Pizotifen is combined with Barbital. Approved Platelet Activating Factor The serum concentration of Platelet Activating Factor can be decreased when it is combined with Barbital. Experimental Polythiazide Barbital may increase the orthostatic hypotensive activities of Polythiazide. Approved Pomalidomide The risk or severity of adverse effects can be increased when Pomalidomide is combined with Barbital. Approved Practolol The serum concentration of Practolol can be decreased when it is combined with Barbital. Approved Pramipexole Barbital may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Barbital is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Barbital is combined with Prazepam. Approved, Illicit Prazosin Barbital may increase the hypotensive activities of Prazosin. Approved Pregabalin The therapeutic efficacy of Barbital can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prenylamine The metabolism of Prenylamine can be increased when combined with Barbital. Withdrawn Prilocaine The risk or severity of adverse effects can be increased when Prilocaine is combined with Barbital. Approved Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Barbital. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Barbital. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Barbital. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Barbital. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Barbital. Approved, Investigational Propacetamol The metabolism of Propacetamol can be increased when combined with Barbital. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Barbital is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Proparacaine is combined with Barbital. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Barbital. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Barbital is combined with Propoxycaine. Approved Propranolol The serum concentration of Propranolol can be decreased when it is combined with Barbital. Approved, Investigational Protriptyline The metabolism of Protriptyline can be increased when combined with Barbital. Approved Proxibarbal The risk or severity of adverse effects can be increased when Barbital is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Barbital is combined with PSD502. Investigational Pyridoxine The metabolism of Barbital can be increased when combined with Pyridoxine. Approved, Investigational, Nutraceutical, Vet Approved Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Barbital. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Barbital. Approved Quinapril Barbital may increase the hypotensive activities of Quinapril. Approved, Investigational Quinethazone Barbital may increase the orthostatic hypotensive activities of Quinethazone. Approved Quinisocaine The risk or severity of adverse effects can be increased when Barbital is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Barbital is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Barbital. Approved, Investigational Ramipril Barbital may increase the hypotensive activities of Ramipril. Approved Rasagiline Barbital may increase the hypotensive activities of Rasagiline. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Barbital. Approved Remoxipride The risk or severity of adverse effects can be increased when Remoxipride is combined with Barbital. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Barbital. Approved, Investigational Rifabutin The metabolism of Barbital can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Barbital can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Barbital can be increased when combined with Rifapentine. Approved, Investigational Rifaximin The metabolism of Barbital can be increased when combined with Rifaximin. Approved, Investigational Riociguat Barbital may increase the hypotensive activities of Riociguat. Approved Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Barbital. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Barbital is combined with Ritanserin. Investigational Romifidine The risk or severity of adverse effects can be increased when Barbital is combined with Romifidine. Vet Approved Ropinirole Barbital may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Barbital. Approved Rotigotine Barbital may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Barbital. Approved Sacubitril Barbital may increase the hypotensive activities of Sacubitril. Approved Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Barbital. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Barbital. Approved, Vet Approved Selegiline Barbital may increase the hypotensive activities of Selegiline. Approved, Investigational, Vet Approved Seletracetam The metabolism of Seletracetam can be increased when combined with Barbital. Investigational Sepranolone The risk or severity of adverse effects can be increased when Barbital is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Barbital is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Barbital is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Barbital. Approved, Vet Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Barbital. Approved Somatostatin The risk or severity of adverse effects can be increased when Somatostatin is combined with Barbital. Approved, Investigational Sotalol The serum concentration of Sotalol can be decreased when it is combined with Barbital. Approved Spironolactone Barbital may increase the hypotensive activities of Spironolactone. Approved Stiripentol The risk or severity of adverse effects can be increased when Stiripentol is combined with Barbital. Approved Streptokinase Barbital may increase the hypotensive activities of Streptokinase. Approved, Investigational Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Barbital. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Barbital. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Barbital is combined with Sultopride. Experimental Suvorexant Barbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Synthetic Conjugated Estrogens, A The therapeutic efficacy of Synthetic Conjugated Estrogens, A can be decreased when used in combination with Barbital. Approved Talinolol The serum concentration of Talinolol can be decreased when it is combined with Barbital. Investigational Tamsulosin Barbital may increase the hypotensive activities of Tamsulosin. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Barbital is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Barbital. Approved Tasimelteon The risk or severity of adverse effects can be increased when Tasimelteon is combined with Barbital. Approved, Investigational Telmisartan Barbital may increase the hypotensive activities of Telmisartan. Approved, Investigational Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Barbital. Approved, Investigational Teniposide The serum concentration of Teniposide can be decreased when it is combined with Barbital. Approved Terazosin Barbital may increase the hypotensive activities of Terazosin. Approved Terodiline The metabolism of Terodiline can be increased when combined with Barbital. Experimental Tertatolol The serum concentration of Tertatolol can be decreased when it is combined with Barbital. Experimental Tetrabenazine The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Barbital. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Barbital is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Barbital is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Barbital is combined with Tetrodotoxin. Investigational Thalidomide Barbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Theophylline The serum concentration of Theophylline can be decreased when it is combined with Barbital. Approved Thiamylal The risk or severity of adverse effects can be increased when Thiamylal is combined with Barbital. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Thiopental is combined with Barbital. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Barbital. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Barbital. Approved Tiagabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Barbital. Approved, Investigational Tianeptine The metabolism of Tianeptine can be increased when combined with Barbital. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Barbital is combined with Tiapride. Approved, Investigational Tiletamine The risk or severity of adverse effects can be increased when Barbital is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Barbital is combined with Tilidine. Experimental Timolol The serum concentration of Timolol can be decreased when it is combined with Barbital. Approved Tioclomarol The metabolism of Tioclomarol can be increased when combined with Barbital. Experimental Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Barbital. Approved, Investigational Tolazoline Barbital may increase the hypotensive activities of Tolazoline. Approved, Vet Approved Tolcapone Barbital may increase the hypotensive activities of Tolcapone. Approved, Withdrawn Tolfenamic Acid The metabolism of Tolfenamic Acid can be increased when combined with Barbital. Approved, Investigational Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Barbital. Approved Torasemide Barbital may increase the hypotensive activities of Torasemide. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Barbital. Approved, Investigational Trandolapril Barbital may increase the hypotensive activities of Trandolapril. Approved Tranilast The metabolism of Tranilast can be increased when combined with Barbital. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Barbital. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Trazodone is combined with Barbital. Approved, Investigational Tretinoin Barbital may increase the hypotensive activities of Tretinoin. Approved, Investigational, Nutraceutical Triamterene Barbital may increase the hypotensive activities of Triamterene. Approved Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Barbital. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Barbital is combined with Tricaine methanesulfonate. Vet Approved Trichlormethiazide Barbital may increase the orthostatic hypotensive activities of Trichlormethiazide. Approved, Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Barbital is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Barbital. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Barbital is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Barbital. Approved, Vet Approved Trimebutine The metabolism of Trimebutine can be increased when combined with Barbital. Approved Trimethadione The metabolism of Trimethadione can be increased when combined with Barbital. Approved Trimipramine The metabolism of Trimipramine can be increased when combined with Barbital. Approved Triprolidine The risk or severity of adverse effects can be increased when Triprolidine is combined with Barbital. Approved Ulipristal The serum concentration of Ulipristal can be decreased when it is combined with Barbital. Approved Valproic Acid The serum concentration of Barbital can be increased when it is combined with Valproic Acid. Approved, Investigational Valsartan Barbital may increase the hypotensive activities of Valsartan. Approved, Investigational Venlafaxine The risk or severity of adverse effects can be increased when Barbital is combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Barbital is combined with Veralipride. Experimental Verapamil The metabolism of Verapamil can be increased when combined with Barbital. Approved Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Barbital. Approved Vinpocetine The metabolism of Vinpocetine can be increased when combined with Barbital. Investigational Vinyl ether The risk or severity of adverse effects can be increased when Barbital is combined with Vinyl ether. Experimental Voriconazole The serum concentration of Voriconazole can be decreased when it is combined with Barbital. Approved, Investigational Vortioxetine The risk or severity of adverse effects can be increased when Barbital is combined with Vortioxetine. Approved, Investigational Warfarin The metabolism of Warfarin can be increased when combined with Barbital. Approved WIN 55212-2 The metabolism of WIN 55212-2 can be increased when combined with Barbital. Experimental Xenon The risk or severity of adverse effects can be increased when Barbital is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Barbital is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Barbital. Approved, Illicit, Investigational Ziconotide The metabolism of Ziconotide can be increased when combined with Barbital. Approved Zimelidine The risk or severity of adverse effects can be increased when Barbital is combined with Zimelidine. Withdrawn Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Barbital. Approved Zolazepam The risk or severity of adverse effects can be increased when Barbital is combined with Zolazepam. Vet Approved Zolpidem Barbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Barbital. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Barbital. Approved Zotepine The risk or severity of adverse effects can be increased when Barbital is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Barbital. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- ATC Codes
- N05CA04 — Barbital
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 190 °C PhysProp boiling point (°C) 250 °C at 2.20E+01 mm Hg PhysProp water solubility 7460 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 0.65 HANSCH,C ET AL. (1995) logS -1.39 ADME Research, USCD pKa 8.14 (at 15 °C) KORTUM,G ET AL (1961) - Predicted Properties
Property Value Source Water Solubility 3.23 mg/mL ALOGPS logP 0.73 ALOGPS logP 0.72 ChemAxon logS -1.8 ALOGPS pKa (Strongest Acidic) 8.48 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 75.27 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 44.25 m3·mol-1 ChemAxon Polarizability 17.59 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.955 Blood Brain Barrier + 0.9694 Caco-2 permeable - 0.6146 P-glycoprotein substrate Non-substrate 0.5238 P-glycoprotein inhibitor I Non-inhibitor 0.7826 P-glycoprotein inhibitor II Non-inhibitor 0.9964 Renal organic cation transporter Non-inhibitor 0.9395 CYP450 2C9 substrate Non-substrate 0.7915 CYP450 2D6 substrate Non-substrate 0.9074 CYP450 3A4 substrate Non-substrate 0.7823 CYP450 1A2 substrate Non-inhibitor 0.896 CYP450 2C9 inhibitor Non-inhibitor 0.9436 CYP450 2D6 inhibitor Non-inhibitor 0.9586 CYP450 2C19 inhibitor Non-inhibitor 0.918 CYP450 3A4 inhibitor Non-inhibitor 0.9723 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9847 Ames test AMES toxic 0.5531 Carcinogenicity Non-carcinogens 0.8532 Biodegradation Not ready biodegradable 0.9462 Rat acute toxicity 3.5489 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9913 hERG inhibition (predictor II) Non-inhibitor 0.9734
Spectra
- Mass Spec (NIST)
- Download (8.31 KB)
- Spectra
Spectrum Spectrum Type Splash Key GC-MS Spectrum - CI-B GC-MS splash10-000i-0900000000-90fb45d882d2c3ed038f GC-MS Spectrum - EI-B GC-MS splash10-052f-9400000000-fa1289872f9f35015abc GC-MS Spectrum - EI-B GC-MS splash10-052f-9500000000-856a7fe5dbfd28d00c38 GC-MS Spectrum - EI-B GC-MS splash10-0a4l-2900000000-42c0874d0bac13cc2d94 GC-MS Spectrum - EI-B GC-MS splash10-0a4u-5900000000-497f9ee367181a6df30a Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazines
- Sub Class
- Pyrimidines and pyrimidine derivatives
- Direct Parent
- Barbituric acid derivatives
- Alternative Parents
- N-acyl ureas / Diazinanes / Dicarboximides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Barbiturate / N-acyl urea / Ureide / 1,3-diazinane / Dicarboximide / Urea / Carbonic acid derivative / Carboxylic acid derivative / Azacycle / Organic nitrogen compound
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- barbiturates (CHEBI:31252)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRA1
- Uniprot ID
- P14867
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-1
- Molecular Weight
- 51801.395 Da
References
- Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514]
- Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
- Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
- Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA2
- Uniprot ID
- P47869
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-2
- Molecular Weight
- 51325.85 Da
References
- Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
- Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA3
- Uniprot ID
- P34903
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-3
- Molecular Weight
- 55164.055 Da
References
- Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
- Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA4
- Uniprot ID
- P48169
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-4
- Molecular Weight
- 61622.645 Da
References
- Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Transporter activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA5
- Uniprot ID
- P31644
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-5
- Molecular Weight
- 52145.645 Da
References
- Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
- Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA6
- Uniprot ID
- Q16445
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-6
- Molecular Weight
- 51023.69 Da
References
- Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
- Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Ligand-gated ion channel activity
- Specific Function
- After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
- Gene Name
- CHRNA4
- Uniprot ID
- P43681
- Uniprot Name
- Neuronal acetylcholine receptor subunit alpha-4
- Molecular Weight
- 69956.47 Da
References
- Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
- Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
- Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Toxic substance binding
- Specific Function
- After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The cha...
- Gene Name
- CHRNA7
- Uniprot ID
- P36544
- Uniprot Name
- Neuronal acetylcholine receptor subunit alpha-7
- Molecular Weight
- 56448.925 Da
References
- Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
- Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
- Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Ionotropic glutamate receptor activity
- Specific Function
- Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory ne...
- Gene Name
- GRIA2
- Uniprot ID
- P42262
- Uniprot Name
- Glutamate receptor 2
- Molecular Weight
- 98820.32 Da
References
- Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
- Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Kainate selective glutamate receptor activity
- Specific Function
- Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a co...
- Gene Name
- GRIK2
- Uniprot ID
- Q13002
- Uniprot Name
- Glutamate receptor ionotropic, kainate 2
- Molecular Weight
- 102582.475 Da
References
- Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
- Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Drug created on July 31, 2007 07:09 / Updated on May 01, 2018 22:25